1.	Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571AUS177, US177, RIGHT Trial, NCT00081926
2.	Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) Phase: Phase IV Type: Treatment Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571BJP07, NCT00171977
3.	Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571ACA09, NCT00171899
4.	Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107FJP01, NCT01043874
5.	Imatinib in KIT-negative Systemic Mastocytosis Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EudraCT 2010-019189-94, NCT01297777
6.	STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 to 70 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CDR0000068089, NOVARTIS-CSTI5710106, FHCRC-1556.00, NCT00006343
7.	Phase III Randomized Study of Two Different Doses of Imatinib Mesylate in Patients With CD117-Expressing Metastatic or Unresectable Gastrointestinal Stromal Tumor Phase: Phase III Type: Treatment Status: Closed Age: 15 and over Sponsor: NCI Protocol IDs: CLB-80004, CAN-NCIC-S0033, E-S0033, SWOG-S0033, INT-S0033, NCT00009906, S0033
8.	Phase II Pilot Study of Intensified Chemotherapy With or Without Allogeneic Hematopoietic Stem Cell Transplantation in Children With Very High-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 1 to 21 Sponsor: NCI Protocol IDs: COG-AALL0031, NCT00022737, AALL0031
9.	A Phase III Randomized Double-Blind Study of Adjuvant Imatinib Mesylate (Gleevec; STI571) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ACOSOG-Z9001, CAN-NCIC-SRC1, CALGB-ACOSOG-Z9001, SWOG-ACOSOG-Z9001, NCT00041197, UWCC-UW-6303, UWCC-UW-03-8438-A-03, SRC1
10.	Phase III Randomized Study of Allogeneic or Autologous Stem Cell Transplantation Versus Conventional Consolidation and Maintenance Chemotherapy in Patients With Acute Lymphoblastic Leukemia in First Remission Phase: Phase III Type: Treatment Status: Completed Age: 15 to 65 Sponsor: NCI Protocol IDs: ECOG-2993, MRC-LEUK-UKALL-XII, EST-4491, INT-0132, NCT00002514
11.	Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SSGXVIII/AIO, NCT00116935
12.	Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Phase: Phase III Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571BDE40, NCT00154375
13.	Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CECOG/GIST 1.2.001, CSTI571BIC07, NCT00293124
14.	Phase III Randomized Study of Imatinib Mesylate in Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0511009-01, NOVARTIS-CSTI571K2301, EUDRACT-2005-00657-29, FWA00004642, NCT00324636
15.	S0502 Imatinib Mesylate With or W/O Bevacizumab in Treating Patients With Metastatic or Unresectable GIST Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000482236, U10CA032102, S0502, CALGB-S0502, CAN-NCIC-S0502, SWOG-S0502, NCT00324987
16.	Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CST1571BFR14, ET2002-021, NCT00367861
17.	A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-056, 2006-005712-27, NCT00481247
18.	Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3160A4-3000, B1871008, NCT00574873
19.	Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000596490, EORTC-62005, AGITG-AGO102-GIST, ISG-62005, SSG-15, NCT00685828
20.	Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107G2301, NCT00785785
21.	STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 15 and over Sponsor: Other Protocol IDs: EORTC-62001-16003, EORTC-62001, EORTC-16003, NOVARTIS-CSTI5710203, NCT00006357
22.	Phase I/II Study of Imatinib Mesylate in Patients With Recurrent Malignant Glioma or Meningioma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-9908, NCI-01-C-0243, UCLA-0101024, NCT00010049
23.	Phase I/II Study of Imatinib Mesylate and High-Dose Cytarabine in Patients With Blastic Phase Chronic Myelogenous Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCLA-0011009, UCLA-NCI-1870, NCI-1870, NCT00015834, 1870
24.	Phase I/II Study of Imatinib Mesylate Combined With Daunorubicin, Vincristine, and Prednisone in Patients With Lymphoid Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCLA-0011010, UCLA-NCI-4292, NCI-4292, NCT00015860, 4292
25.	Phase I/II Study of Imatinib Mesylate and Cytarabine in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: CKTO-2001-03, HOVON-51CML, EU-20132, HOVON-CKTO-2001-03, NOVARTIS-CST1571ANL01, NCT00028847